Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
26/10/2026
Coinbase Global said some users may currently be unable to convert Brazilian reais for buying and selling cryptocurrencies on Coinbase.
Latest
3 m ago
U.S. Stocks on the Move | Nasdaq Composite Index Extends Gains to 1.2%; Semiconductor Stocks Rise
4 m ago
Merck announced results from the Phase III TroFuse-005 clinical trial: its investigational TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), compared with chemotherapy, reduced the risk of death by 32% and the risk of disease progression or death by 41% in patients with advanced or recurrent endometrial cancer who had previously received platinum-containing chemotherapy and anti-PD-1/L1 immunotherapy. Median overall survival was 19.0 months, 6.9 months longer than the 12.1 months in the chemotherapy group; median progression-free survival was 7.2 months, 3.3 months longer than the 3.9 months in the chemotherapy group. The objective response rate was 35.1%, higher than the 17.3% in the chemotherapy group. The study enrolled 776 patients. The U.S. FDA has accepted the Biologics License Application for this drug for the relevant patient population and granted priority review, with a target decision date of June 15, 2027.
4 m ago
Hengli Hydraulic (601100.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 2.154 billion yuan, a year-on-year increase of 3.2%.
4 m ago
Bozhong Precision (688097.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 492 million yuan, a year-on-year increase of 47.96%.
5 m ago
Siglent Technologies (688112.SH) released its performance for the first three quarters, with net profit attributable to shareholders of RMB 154 million, a year-on-year increase of 38.27%.
See all latest